Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aQIVc in Older Adults ≥50 Years of Age
NCT05501561Phase 2Completed
- Sponsor
- CSL Seqirus
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of Influenza vaccine surface antigen adjuvanted with MF59 in influenza, sponsored by CSL Seqirus. Started Aug 2022; status: completed.
02
Drugs
Influenza vaccine surface antigen adjuvanted with MF59
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05501561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501561.